Verix named Top AI-Powered Pharma Platform 2026 by Pharma Tech Outlook Citius Oncology selects Verix Tovana to launch LYMPHIR cancer treatment Verix GenAI Database Explorer lets pharma teams ask data questions in plain English Blue Pumpkin Software acquired by Witness Systems for $75M in 2005 Bayer. Novartis. Roche. GSK. All run on Tovana. Doron Aspitz: Pioneer of the Year, Call Center Magazine Verix acquires start-up.ai to build pharma-trained LLMs in-house Verix named Top AI-Powered Pharma Platform 2026 by Pharma Tech Outlook Citius Oncology selects Verix Tovana to launch LYMPHIR cancer treatment Verix GenAI Database Explorer lets pharma teams ask data questions in plain English Blue Pumpkin Software acquired by Witness Systems for $75M in 2005 Bayer. Novartis. Roche. GSK. All run on Tovana. Doron Aspitz: Pioneer of the Year, Call Center Magazine Verix acquires start-up.ai to build pharma-trained LLMs in-house

Profile • Technology Executive • Los Altos, CA

Doron
Aspitz

President & CEO, Verix — the AI that tells pharma what to do next

Two companies. Two pivots. One thesis: data beats intuition every time. From workforce software to pharmaceutical decision intelligence, Doron Aspitz has spent 20 years building systems that tell organizations what to do before they know they need to ask.

Founder $12.7M Raised Pharma AI $75M Exit Pioneer of the Year

Doron Aspitz • Santa Clara, California

$75M Blue Pumpkin exit value

$12.7M Verix total funding

4X Reported client ROI, Year 1

20+ Years building data companies

The Profile

When your second act is harder than your first

Before Doron Aspitz was telling pharmaceutical sales teams where to deploy their reps, he was solving a completely different problem: how do you know when to schedule a call-center agent's break? That question - mundane on its surface, operationally critical in practice - led to Blue Pumpkin Software, a company he co-founded in 2000 that became one of the leading workforce management platforms for contact centers. He built it through the dot-com crash, kept it profitable while competitors folded, and sold it to Witness Systems (NASDAQ: WITS) for approximately $75 million in January 2005.

Most founders would have taken a victory lap. Aspitz took a harder road. The same year Blue Pumpkin sold, he started Verix - a bet that the pharmaceutical industry's commercial operations problem looked a lot like the workforce scheduling problem: enormous complexity, expensive decisions made on incomplete information, and data everywhere but insight nowhere.

What connected those two industries wasn't the surface feature set. It was the underlying logic: when you have thousands of people making thousands of decisions every day, intuition doesn't scale. Rules-based systems get gamed. Dashboards get ignored. What actually changes behavior is a system that tells you, specifically and confidently, what action to take next. Blue Pumpkin did that for call-center agents. Verix does it for pharmaceutical sales representatives calling on healthcare providers.

Aspitz grew up in Israel, where he completed both a B.Sc. in Economics and Statistics and a Master's in Management Information Systems at Tel Aviv University. That combination - the economist's training in incentives and the information systems architect's training in data pipelines - runs through everything he's built since. He came up through senior roles at Tandem Corporation and IBM before striking out on his own, which gave him both the technical vocabulary and the enterprise sales instincts that early-stage B2B companies rarely develop fast enough.

Call Center Magazine gave him its "Pioneer of the Year" award for his work at Blue Pumpkin. The citation recognized his contributions to workforce optimization technology in a period when the industry was still figuring out what software-driven scheduling could even mean. That framing - pioneer, not just practitioner - stuck, and the pattern repeated at Verix.

Location: Los Altos, California

Education: Tel Aviv University (B.Sc. Economics & Statistics; M.S. MIS)

First exit: Blue Pumpkin Software → Witness Systems, ~$75M (2005)

Current company: Verix, founded 2004, Santa Clara

Key clients: Bayer, Novartis, Roche, GSK

Award: Pioneer of the Year, Call Center Magazine

Writing: Contributor, MedCity News

Personality

Customer-centric Visionary Data-driven Cross-industry thinker Serial founder

Education

M.S. Management Information Systems

Tel Aviv University

B.Sc. Economics & Statistics

Tel Aviv University

"Verix is not a conventional analytics solution - it's a decision engine."

- Doron Aspitz, President & CEO, Verix

The Company

Tovana: the engine behind pharma's next best action

The pharmaceutical industry has a strange problem. It is simultaneously one of the most data-rich and most data-paralyzed industries on the planet. A single mid-sized pharma company might have data from claims, electronic health records, prescription trends, sales force activity, market research, and patient support programs - all in separate systems, all requiring different specialists to interpret, and none of it updating fast enough to be actionable by the time a sales rep is standing in a physician's waiting room.

Verix's Tovana platform was built specifically for that gap. Aspitz describes it not as analytics software but as a decision engine - a distinction he holds firmly. Analytics tells you what happened. A decision engine tells you what to do. Tovana ingests commercial pharma data, applies machine learning models trained specifically on life sciences datasets, and surfaces prioritized actions: which healthcare providers to target, which channels to use, which messages will move the needle on prescribing behavior.

In March 2024, Aspitz launched the GenAI Database Explorer on top of Tovana - allowing commercial teams to query their own data in plain English. Ask it which HCPs are showing early adoption signals in a specific therapeutic area. Ask it where your field force should focus next quarter. The technical moat isn't the language model itself - it's the pharma-specific training data and the integration layer that makes the answers trustworthy enough to act on.

That trustworthiness comes, in part, from the 2023 acquisition of start-up.ai - a specialist AI firm that had been a Verix partner. Aspitz brought the team in-house rather than continuing to license their capabilities. The rationale was direct: if the LLMs powering your commercial decisions need to understand clinical trial data, patient journey patterns, and HCP engagement dynamics, you can't outsource that understanding.

Verix Tovana Platform

Patented AI decision engine for pharmaceutical commercial operations. Machine learning + pharma-trained LLMs + no-code interface = field teams that know what to do before the competition does.

HCP Targeting

Identifies which healthcare providers represent the highest-opportunity segments for specific brands and indications.

Patient Finder

Surfaces patient identification signals from claims and Rx data to guide field force prioritization.

Omnichannel

Coordinates rep visits, digital outreach, and sampling to maximize engagement across every channel simultaneously.

Bayer • Novartis • Roche • GSK and other Fortune 500 pharmaceutical companies rely on Verix Tovana for commercial strategy execution.

First Act

Blue Pumpkin: building something worth buying

Blue Pumpkin Software didn't get famous for its name. It got acquired for $75 million because Aspitz built it to be profitable and resilient during the years when the rest of the enterprise software industry was imploding. The company's workforce management solutions for contact centers solved a specific, measurable problem: scheduling agents at the right time, in the right numbers, with the right skills, to handle call volume that was inherently unpredictable.

The 2005 acquisition by Witness Systems (NASDAQ: WITS) - a deal worth approximately $40 million in cash and the remainder in stock - validated the approach. Witness Systems was building out a full suite of contact center intelligence tools, and Blue Pumpkin's workforce management capabilities were a missing piece. The integration made strategic sense on both sides.

What Aspitz carried from Blue Pumpkin to Verix wasn't just a track record. It was a methodology: find industries where decisions are made manually that should be made systematically, build the system that makes those decisions better, and get out of the way. The contact center was one such industry. Pharmaceutical commercial operations turned out to be another - bigger, more complex, and harder to crack.

Blue Pumpkin at a Glance

Co-founded circa 2000 as a workforce management platform for contact centers
Built to profitability through the dot-com crash - rare among tech companies of that era
Acquired by Witness Systems (NASDAQ: WITS) in January 2005 for ~$75 million
Deal structured as ~$40M cash + stock
Aspitz won Call Center Magazine's "Pioneer of the Year" award for his contributions during this period

How It Works

From raw data to field action in four steps

Data Unification

Claims, EHR, Rx trends, sales force activity - all ingested and unified into a single commercial data foundation

AI Modeling

Pharma-trained ML models score HCPs, patients, and opportunities - updated in real time as new data flows in

Decision Engine

Tovana surfaces the next best action for every rep, every territory, every brand - no manual analysis required

Field Execution

Reps receive prioritized targets and channel guidance; results feed back into the model, sharpening future recommendations

Career Arc

A timeline of well-timed bets

Early Career

Senior technical and global business roles at IBM and Tandem Corporation - building enterprise instincts before founding anything

2000

Co-founds Blue Pumpkin Software. Workforce management for contact centers during the post-dot-com crunch.

2004

Recognized as "Pioneer of the Year" by Call Center Magazine. Also: founds Verix - starts building for pharma while Blue Pumpkin is still running.

2005

Blue Pumpkin acquired by Witness Systems (NASDAQ: WITS) for ~$75M. Aspitz shifts full attention to Verix.

2019

Verix closes convertible note round, bringing total funding raised to $12.7M. Investors include Gemini Israel Ventures, Advent Venture Partners, and Viola Group.

2023

Acquires AI specialist firm start-up.ai, bringing pharma-trained LLM capabilities in-house.

2024

Launches GenAI Database Explorer on Tovana - natural language querying of commercial pharma data. Writes for MedCity News on AI's role in marketing precision genetic drugs.

2025

Citius Oncology partners with Verix to commercialize LYMPHIR (denileukin diftitox-cxdl), a cancer treatment - one of the highest-stakes Tovana deployments to date.

2026

Pharma Tech Outlook names Verix Top AI-Powered Pharma Platform 2026.

Achievements

What the record shows

Co-founded Blue Pumpkin Software, grew it to a ~$75M acquisition by Witness Systems in 2005
Won "Pioneer of the Year" from Call Center Magazine for contributions to workforce optimization
Built Verix Tovana into the platform of choice for global pharma leaders: Bayer, Novartis, Roche, GSK
Grew Verix to 63 employees and ~$3.5M annual revenue on just $12.7M in total funding
Launched pharma's first GenAI Database Explorer in 2024, enabling natural-language commercial data queries
Acquired AI specialist firm start-up.ai to own pharma-trained LLM capabilities
Achieved reported ~4X first-year ROI for clients across Tovana deployments
Recognized as Top AI-Powered Pharma Platform 2026 by Pharma Tech Outlook

"Verix operates on $12.7M in total funding while serving the same Fortune 500 pharma companies that spend billions annually on commercial operations. That gap is Aspitz's competitive argument in every sales call."

- YesPress analysis

Behind the Decisions

Three moments that shaped how he builds

Surviving the crash by staying boring

While dot-com companies were burning through venture money chasing growth at any cost, Blue Pumpkin ran lean and focused on profitable revenue. When the market collapsed in 2000-2001, Blue Pumpkin kept scaling. The discipline of that era shaped how Aspitz thinks about capital efficiency - Verix's entire journey on $12.7M total reflects the same instinct.

Bringing start-up.ai inside the fence

When Aspitz decided to acquire start-up.ai, he was essentially buying back the capability he'd been renting. The rationale wasn't cost - it was control. Pharma commercial AI needs to be tuned to specific datasets, regulatory constraints, and therapeutic context. You can't maintain that tuning through a licensing relationship. You have to own the team that does the tuning.

Citius Oncology: the stakes went up

The November 2025 Citius Oncology partnership put Tovana at the center of commercializing LYMPHIR, a cancer treatment. This is pharma AI at its most consequential: the difference between a well-executed commercial launch and a poor one affects how many patients find their way to a treatment. Aspitz has said very little publicly about this deployment. The partnership itself does the talking.

Worth knowing

Fun facts & less-obvious details

Aspitz holds degrees in both Economics and Statistics AND Management Information Systems from Tel Aviv University - the economist's eye for incentives plus the systems architect's eye for data, in one person.

"Tovana" is the Hebrew word for understanding or intelligence. For an Israeli founder building decision intelligence for American pharma companies, the name is either a quiet joke or a sincere statement of purpose. Probably both.

Before pharma, Aspitz optimized call-center scheduling. The industries look nothing alike. The underlying problem - thousands of actors making thousands of decisions without enough signal - is identical.

Verix has raised just $12.7M total since 2004. Most enterprise SaaS companies at its market position would have raised 10x that. Aspitz's capital efficiency is either a constraint or a competitive flex. His clients treat it like the latter.

He writes for MedCity News under the author handle @daspit - a rare CEO who publishes thought leadership on the technical challenges his own platform is solving, including precision medicine commercialization and AI integration in pharma sales.

Senior roles at IBM and Tandem Corporation preceded the founding era. That's not just resume decoration - enterprise software companies are built by people who know how enterprise software actually gets purchased, deployed, and used.

Topics & Context

Where Aspitz plays

Aspiration

Where this is heading

To establish AI-driven decision intelligence as the standard operating model for pharmaceutical commercial teams globally - replacing static dashboards with action-oriented, real-time intelligence that accelerates how drugs reach patients who need them.

The Citius Oncology partnership for LYMPHIR's commercial launch is the clearest signal yet that Aspitz is moving Verix upstream - from analytics vendor to strategic commercial partner for launches that matter.

Connections